The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly | Zendy

Cornelis H. van Werkhoven | Zendy; Susanne M. Huijts | Zendy; Marieke Bolkenbaas | Zendy; Diederick E. Grobbee | Zendy; Marc J. M. Bonten | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly

Author(s) -

Cornelis H. van Werkhoven,

Susanne M. Huijts,

Marieke Bolkenbaas,

Diederick E. Grobbee,

Marc J. M. Bonten

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ686

Subject(s) - medicine , pneumococcal disease , pneumococcal conjugate vaccine , vaccination , streptococcus pneumoniae , pneumococcal pneumonia , pneumonia , immunization , pneumococcal infections , pneumococcal vaccine , vaccine efficacy , immunology , pediatrics , antibiotics , antigen , microbiology and biotechnology , biology

In a post hoc analysis of the Community-Acquired Pneumonia (CAP) immunization Trial in Adults the model-predicted 13-valent pneumococcal conjugate vaccine efficacy for preventing vaccine-type specific CAP and Invasive Pneumococcal Disease declined from 65% to 40% for subjects being 65 and 75 year olds at the time of vaccination, respectively.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research